{
  "variants": [
    {
      "gene": "SNCA",
      "variant": "A30P",
      "protein_change": {
        "reference": "Alanine",
        "alternate": "Proline",
        "position": 30
      },
      "variant_string_id": "SNCA A30P",
      "functional_evidence": {
        "step_1": {
          "judgment": "Yes",
          "reason": "The paper explicitly links A30P to altered phospholipid binding and increased toxicity in Parkinson's disease, establishing a clear disease mechanism."
        },
        "step_2": {
          "judgment": "Yes",
          "reason": "Solution NMR (a validated assay for protein-lipid interactions) is directly relevant to the mechanism of phospholipid binding and synaptic vesicle regulation."
        },
        "step_3": {
          "sub_step_3a": {
            "judgment": "No",
            "reason": "The abstract does not explicitly mention controls or replicates (e.g., wild-type or benign variant comparisons)."
          },
          "sub_step_3b": {
            "judgment": "Yes",
            "reason": "NMR spectroscopy is a broadly accepted technique in the field, and the study's findings align with prior biophysical studies (e.g., altered binding affinities)."
          },
          "strength": "Max PS3_supporting / Max BS3_supporting"
        },
        "step_4": {
          "sub_step_4a": {
            "judgment": "No",
            "reason": "The abstract does not provide OddsPath values or statistical metrics (e.g., p-values, confidence intervals)."
          },
          "sub_step_4b": {
            "judgment": "Unknown",
            "reason": "The number of benign/pathogenic controls is not explicitly stated in the abstract."
          },
          "strength": "PS3_supporting"
        },
        "conclusion": "The A30P variant shows altered phospholipid binding compared to wild-type, correlating with increased toxicity in Parkinson's disease. This supports pathogenicity (PS3_supporting)."
      }
    },
    {
      "gene": "SNCA",
      "variant": "E46K",
      "protein_change": {
        "reference": "Glutamic acid",
        "alternate": "Lysine",
        "position": 46
      },
      "variant_string_id": "SNCA E46K",
      "functional_evidence": {
        "step_1": {
          "judgment": "Yes",
          "reason": "The paper explicitly links E46K to altered phospholipid binding and increased toxicity in Parkinson's disease, establishing a clear disease mechanism."
        },
        "step_2": {
          "judgment": "Yes",
          "reason": "Solution NMR (a validated assay for protein-lipid interactions) is directly relevant to the mechanism of phospholipid binding and synaptic vesicle regulation."
        },
        "step_3": {
          "sub_step_3a": {
            "judgment": "No",
            "reason": "The abstract does not explicitly mention controls or replicates (e.g., wild-type or benign variant comparisons)."
          },
          "sub_step_3b": {
            "judgment": "Yes",
            "reason": "NMR spectroscopy is a broadly accepted technique in the field, and the study's findings align with prior biophysical studies (e.g., altered binding affinities)."
          },
          "strength": "Max PS3_supporting / Max BS3_supporting"
        },
        "step_4": {
          "sub_step_4a": {
            "judgment": "No",
            "reason": "The abstract does not provide OddsPath values or statistical metrics (e.g., p-values, confidence intervals)."
          },
          "sub_step_4b": {
            "judgment": "Unknown",
            "reason": "The number of benign/pathogenic controls is not explicitly stated in the abstract."
          },
          "strength": "PS3_supporting"
        },
        "conclusion": "The E46K variant shows altered phospholipid binding compared to wild-type, correlating with increased toxicity in Parkinson's disease. This supports pathogenicity (PS3_supporting)."
      }
    },
    {
      "gene": "SNCA",
      "variant": "A53T",
      "protein_change": {
        "reference": "Alanine",
        "alternate": "Threonine",
        "position": 53
      },
      "variant_string_id": "SNCA A53T",
      "functional_evidence": {
        "step_1": {
          "judgment": "Yes",
          "reason": "The paper explicitly links A53T to altered phospholipid binding and increased toxicity in Parkinson's disease, establishing a clear disease mechanism."
        },
        "step_2": {
          "judgment": "Yes",
          "reason": "Solution NMR (a validated assay for protein-lipid interactions) is directly relevant to the mechanism of phospholipid binding and synaptic vesicle regulation."
        },
        "step_3": {
          "sub_step_3a": {
            "judgment": "No",
            "reason": "The abstract does not explicitly mention controls or replicates (e.g., wild-type or benign variant comparisons)."
          },
          "sub_step_3b": {
            "judgment": "Yes",
            "reason": "NMR spectroscopy is a broadly accepted technique in the field, and the study's findings align with prior biophysical studies (e.g., altered binding affinities)."
          },
          "strength": "Max PS3_supporting / Max BS3_supporting"
        },
        "step_4": {
          "sub_step_4a": {
            "judgment": "No",
            "reason": "The abstract does not provide OddsPath values or statistical metrics (e.g., p-values, confidence intervals)."
          },
          "sub_step_4b": {
            "judgment": "Unknown",
            "reason": "The number of benign/pathogenic controls is not explicitly stated in the abstract."
          },
          "strength": "PS3_supporting"
        },
        "conclusion": "The A53T variant shows altered phospholipid binding compared to wild-type, correlating with increased toxicity in Parkinson's disease. This supports pathogenicity (PS3_supporting)."
      }
    }
  ]
}